SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in four upcoming virtual investor conferences.
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.